Last Price$2.61NASDAQ Previous Close - Last Trade as of 3:57PM ET 1/26/22

Today's Change-0.07(2.61%)
Bid (Size)$2.00 (1)
Ask (Size)$3.71 (1)
Day Low / High$2.57 - 2.82
Volume3.9 M

View Biotechnology IndustryPeer Comparison as of 01/26/2022


Agenus Inc ( NASDAQ )

Price: $2.61
Change: -0.07 (2.61%)
Volume: 3.9 M
3:57PM ET 1/26/2022

Ocugen Inc ( NASDAQ )

Price: $3.15
Change: -0.23 (6.80%)
Volume: 15.0 K
3:57PM ET 1/26/2022

Rapt Therapeutics Inc ( NASDAQ )

Price: $21.41
Change: +0.01 (0.05%)
Volume: 311.6 K
4:00PM ET 1/26/2022

Seres Therapeutics Inc ( NASDAQ )

Price: $7.70
Change: -0.04 (0.52%)
Volume: 948.9 K
3:57PM ET 1/26/2022

MeiraGTx Holdings PLC ( NASDAQ )

Price: $14.22
Change: +0.02 (0.14%)
Volume: 153.1 K
3:56PM ET 1/26/2022

Read more news Recent News

--HC Wainwright Starts Agenus at Buy With $12 Price Target
7:04AM ET 12/16/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Agenus Swings to Q3 Earnings as Revenue Increases; Shares Rise Pre-Bell
8:49AM ET 11/09/2021 MT Newswires

Agenus (AGEN) on Tuesday swung to Q3 earnings of $0.72 per share from a loss of $0.28 per share a year earlier. Three analysts polled by Capital IQ...

Update: Agenus to Withdraw Biologics License Application for Cervical Cancer Drug Candidate; Shares Slump
2:07PM ET 10/22/2021 MT Newswires

(Updates with share price in second paragraph) Agenus (AGEN) said Friday that it is withdrawing its biologics license application for cervical cancer drug...

Agenus to Withdraw Biologics License Application for Cervical Cancer Drug Candidate; Shares Fall Pre-Bell
9:22AM ET 10/22/2021 MT Newswires

Agenus (AGEN) said Friday it is withdrawing its biologics license application for cervical cancer drug candidate balstilimab at the recommendation of the...

View all Commentary and Analysis

Agenus: Making Another Effort With The FDA
9:53PM ET 1/24/2022 Seeking Alpha

The State Of Biotech In 2022
4:04AM ET 1/03/2022 Seeking Alpha

Agenus Inc. (AGEN) CEO Garo Armen on Q3 2021 Results - Earnings Call Transcript
2:13PM ET 11/09/2021 Seeking Alpha

Agenus: The FDA's Alleged Big Pharma Favoritism May Actually Be A Blessing
11:16AM ET 11/09/2021 Seeking Alpha

Company Profile

Business DescriptionAgenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 31, 1994 and is headquartered in Lexington, MA. View company web site for more details
Address3 Forbes Road
Lexington, Massachusetts 02421-7305
Number of Employees294
Recent SEC Filing01/06/20228-K
Chairman & Chief Executive OfficerGaro H. Armen
Chief Financial & Accounting Officer, VP-FinanceChristine M. Klaskin
Chief Technology OfficerMarc van Dijk
Chief Medical OfficerSteven O’Day

Company Highlights

Price Open$2.70
Previous Close$2.61
52 Week Range$2.44 - 6.79
Market Capitalization$670.3 M
Shares Outstanding256.8 M
SectorHealth Technology
Next Earnings Announcement03/21/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.10
Beta vs. S&P 500N/A
Revenue$36.8 M
Net Profit Margin1.30%
Return on Equity-3.00%

Analyst Ratings as of 12/15/2021

Consensus RecommendationConsensus Icon
Powered by Factset